SOLEUS CAPITAL MASTER FUND, L.P. 13D and 13G filings for Pieris Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-02 09:59 am Sale | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | SOLEUS CAPITAL MASTER FUND, L.P. | 0 0.000% | -50,000 (Position Closed) | Filing |
| 2023-01-27 5:02 pm Purchase | 2023-01-25 | 13G | Pieris Pharmaceuticals, Inc. PIRS | SOLEUS CAPITAL MASTER FUND, L.P. | 50,000 5.400% | 37,500 (+300.00%) | Filing |
| 2023-01-26 5:01 pm Sale | 2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | SOLEUS CAPITAL MASTER FUND, L.P. | 12,500 1.300% | -36,061 (-74.26%) | Filing |
| 2022-01-27 4:30 pm Purchase | 2022-01-24 | 13G | Pieris Pharmaceuticals, Inc. PIRS | SOLEUS CAPITAL MASTER FUND, L.P. | 48,561 5.400% | 48,561 (New Position) | Filing |